FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 150 filers reported holding FATE THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.54 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $306,570 | +94.6% | 41,767 | -0.9% | 0.00% | 0.0% |
Q4 2023 | $157,551 | +75.7% | 42,126 | -0.4% | 0.00% | 0.0% |
Q3 2023 | $89,670 | -53.8% | 42,297 | +3.7% | 0.00% | 0.0% |
Q2 2023 | $194,170 | -15.1% | 40,792 | +1.7% | 0.00% | -50.0% |
Q1 2023 | $228,678 | -42.4% | 40,119 | +2.0% | 0.00% | -33.3% |
Q4 2022 | $396,749 | -55.1% | 39,321 | -0.4% | 0.00% | -50.0% |
Q3 2022 | $884,000 | -8.3% | 39,463 | +1.4% | 0.01% | -14.3% |
Q2 2022 | $964,000 | -38.3% | 38,907 | -3.4% | 0.01% | -22.2% |
Q1 2022 | $1,562,000 | -38.1% | 40,296 | -6.6% | 0.01% | -30.8% |
Q4 2021 | $2,524,000 | -4.1% | 43,131 | -2.9% | 0.01% | -7.1% |
Q3 2021 | $2,633,000 | -32.5% | 44,422 | -1.1% | 0.01% | +7.7% |
Q2 2021 | $3,899,000 | +1.8% | 44,928 | -3.3% | 0.01% | 0.0% |
Q1 2021 | $3,831,000 | -4.2% | 46,464 | +5.6% | 0.01% | -13.3% |
Q4 2020 | $4,001,000 | +133.7% | 43,998 | +2.7% | 0.02% | +87.5% |
Q3 2020 | $1,712,000 | +30.3% | 42,835 | +11.8% | 0.01% | +33.3% |
Q2 2020 | $1,314,000 | +64.7% | 38,306 | +6.7% | 0.01% | +50.0% |
Q1 2020 | $798,000 | +7.4% | 35,913 | -5.5% | 0.00% | +33.3% |
Q4 2019 | $743,000 | +44.8% | 37,988 | +15.0% | 0.00% | +50.0% |
Q3 2019 | $513,000 | -24.0% | 33,034 | -0.7% | 0.00% | -33.3% |
Q2 2019 | $675,000 | -0.7% | 33,263 | -14.0% | 0.00% | 0.0% |
Q1 2019 | $680,000 | +32.8% | 38,679 | -3.1% | 0.00% | +50.0% |
Q4 2018 | $512,000 | -5.7% | 39,933 | +19.9% | 0.00% | 0.0% |
Q3 2018 | $543,000 | +48.0% | 33,317 | +2.9% | 0.00% | +100.0% |
Q2 2018 | $367,000 | +21.9% | 32,374 | +4.9% | 0.00% | 0.0% |
Q1 2018 | $301,000 | +91.7% | 30,864 | +20.2% | 0.00% | 0.0% |
Q4 2017 | $157,000 | +55.4% | 25,683 | +0.5% | 0.00% | – |
Q3 2017 | $101,000 | +31.2% | 25,561 | +8.1% | 0.00% | – |
Q2 2017 | $77,000 | -92.0% | 23,650 | +23788.9% | 0.00% | – |
Q1 2014 | $964,000 | +55.0% | 99 | 0.0% | 0.00% | – |
Q4 2013 | $622,000 | – | 99 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $197,709,000 | 22.51% |
Redmile Group, LLC | 12,957,222 | $758,127,000 | 17.24% |
Grosvenor Holdings, L.L.C. | 1,037,256 | $60,690,000 | 6.28% |
Casdin Capital, LLC | 3,400,000 | $198,934,000 | 5.61% |
Ally Bridge Group (NY) LLC | 270,000 | $15,798,000 | 5.52% |
DAFNA Capital Management LLC | 372,160 | $21,775,000 | 5.48% |
Tri Locum Partners LP | 142,032 | $8,310,000 | 3.27% |
Kynam Capital Management, LP | 95,561 | $5,591,000 | 2.99% |
Artal Group S.A. | 1,800,000 | $105,318,000 | 2.86% |
Bellevue Group AG | 3,775,736 | $220,918,000 | 2.28% |